Effect of dopamine agonists on lactotroph adenomas of the human pituitary

被引:0
作者
Lucia Stefaneanu
Kalman Kovacs
Bernd W. Scheithauer
George Kontogeorgos
Darren L. Riehle
Thomas J. Sebo
David Murray
Sergio Vidal
Ami Tran
Michael Buchfelder
Rudolf Fahlbusch
机构
[1] University of Toronto,Department of Laboratory Medicine, St. Michael’s Hospital
[2] Mayo Clinic,Department of Laboratory Medicine and Pathology
[3] G. Gennimatas General Hospital of Athens,Department of Pathology
[4] University of Erlangen-Nürnberg,Department of Neurosurgery
[5] St. Michael’s Hospital,Division of Pathology
来源
Endocrine Pathology | 2000年 / 11卷
关键词
Adenomas; dopamine agonists; pituitary; proliferation markers; vasculature;
D O I
暂无
中图分类号
学科分类号
摘要
Dopamine (DA) agonists cause reduction of blood prolactin level and tumor shrinkage in most patients with lactotroph adenoma. Our aim was to investigate the cellular mechanism of tumor shrinkage by determining mitotic, MIB-1, p27, and apoptotic indices, as well as microvessel density (MVD), surface microvessel density (SMD), ploidy, and other nuclear parameters. Surgically removed lactotroph adenomas were selected from 29 patients, of whom 19 were treated with oral bromocriptine (BEC), long-acting injectable BEC (BEC-LAR), or quinagolide and 10 were untreated. In treated adenomas mitotic and MIB-1 indices were lower, whereas the apoptotic indices were not significantly higher compared to untreated adenomas. The decrease in MIB-1 labeling reached significance in adenomas exposed to quinagolide (p<0.05). Aside from the BEC-LAR treated group, wherein p27 expression was significantly reduced (p<0.05), p27 expression did not differ significantly between the treated and untreated groups. MVD density was significantly lower in the treated adenomas, whereas the decrease in SMD did not attain significance. The DNA ploidy and most other nuclear parameters did not differ significantly in the two groups. In conclusion, reduction of mitotic and MIB-1 indices indicates that suppression of cell proliferation contributes to tumor shrinkage, whereas p27 protein expression and apoptosis play no major role in the adenoma involution. Further studies are required to explain the effect of DA agonists on MVD and SMD.
引用
收藏
页码:341 / 352
页数:11
相关论文
共 226 条
  • [1] Bevan JS(1992)Dopamine agonists and pituitary tumor shrinkage Endocr Rev 13 220-240
  • [2] Webster J(1993)Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine J Clin Endocrinol Metab 76 484-488
  • [3] Burke CW(1997)Treatment of macroprolactinomas with quinagolide (Norprolac) Annu d’Endocrinol 58 87-94
  • [4] Scanlon MF(1975)Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells Nature 255 497-498
  • [5] Ciccarelli E(1982)Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural and morphometric study J Clin Endocrinol Metab 55 1178-1183
  • [6] Miola C(1991)Dopamine, the dopamine D2 receptor and pituitary tumours Clin Endocrinol 35 455-466
  • [7] Grottoli S(1990)Monoclonal antibody Ki-67: its use in histopathology Histopathology 17 489-503
  • [8] Avataneo T(1984)Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67 J Immunol 133 1710-1715
  • [9] Lancranjan I(1996)The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas Acta Neurochir (Wein) 138 1449-1455
  • [10] Camanni F(1998)Usefulness of markers of cell proliferation in the management of pituitary adenomas Clin Sci 95 29-135